In this context, cisplatin treatment can activate TGF-β to create an immunosuppressive TME and annexin A5 works as an immune checkpoint inhibitor to reprogramme the TME and restore tumour sensitivity by blocking the expression of TGF-β3 [148]. The gene discussed is TGFB3; the disease is neoplasm.